Eluxadoline
Brand names: Viberzi · Active ingredient: Eluxadoline
In short: VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
What is Eluxadoline used for?
VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Eluxadoline dosage
The recommended dosage of VIBERZI is 100 mg taken orally twice daily with food.
The recommended dosage of VIBERZI is 75 mg taken orally twice daily with food in patients:
unable to tolerate the 100 mg dose of VIBERZI .
receiving concomitant OATP1B1 inhibitors
.
with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment
.
with moderate or severe renal impairment (eGFR less than 60 mL/min/1.73 m2); and in patients with end stage renal disease (ESRD) not yet on dialysis (eGFR less than 15 mL/min/1.73 m2) .
Discontinue VIBERZI in patients who develop severe constipation
.
Instruct patients if they miss a dose, take the next dose at the regular time and not to take 2 doses at the same time to make up for a missed dose.
How to take Eluxadoline — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Instruct patients to:
stop VIBERZI immediately and seek medical attention if unusual or severe abdominal pain that may radiate to the back or shoulder with or without nausea and vomiting, develops
.
avoid chronic or acute excessive alcohol use while taking VIBERZI .
stop VIBERZI immediately and seek medical attention if symptoms of a hypersensitivity reaction develop .
stop VIBERZI and immediately call their health care provider if they experience severe constipation .
take one tablet twice daily with food.
if they miss a dose, take the next dose at the regular time. Do not take 2 doses at the same time to make up for a missed dose.
call their healthcare provider if they are unable to tolerate VIBERZI
not take alosetron with VIBERZI or not take loperamide on a ch
r
onic basis with VIBERZI due to the potential for constipation. Loperamide may occasionally be used with VIBERZI for acute management of severe diarrhea, but must be discontinued if constipation develops. …
Warnings & precautions
Do not take this medicine if: VIBERZI is contraindicated in patients:
Without a gallbladder. These patients are at increased risk of developing serious adverse reactions of pancreatitis and/or sphincter of Oddi spasm
With known or suspected biliary duct obstruction; or sphincter of Oddi disease or dysfunction. These patients are at increased risk for sphincter of Oddi spasm .
With alcoholism, alcohol abuse or alcohol addiction, or in patients who drink more than 3 alcoholic beverages per day. These patients are at increased risk for acute pancreatitis .
With a history of pancreatitis; or structural diseases of the pancreas, including known or suspected pancreatic duct obstruction. These patients are at increased risk for acute pancreatitis
.
With a known hypersensitivity reaction to VIBERZI .
With severe hepatic impairment (Child-Pugh Class C). These patients are at risk for significantly increased plasma concentrations of eluxadoline
With a history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction. These patients may be at risk for severe complications of bowel obstruction
.
Pancreatitis, with or without sphincter of Oddi spasm , has been reported in patients taking either the 75 mg or 100 mg dosage of VIBERZI, including serious cases resulting in hospitalization, primarily in patients without a gallbladder. Fatal cases have also been reported in patients without a gallbladder. VIBERZI is contraindicated in patients without a gallbladder . Most of the reported cases of serious pancreatitis occurred within a week of starting treatment with VIBERZI and some developed symptoms after one to two doses.
In patients with a gallbladder, evaluate a patient’s alcohol intake prior to starting VIBERZI. Instruct patients to avoid chronic or acute excessive alcohol use while taking VIBERZI. …
Eluxadoline side effects
The following adverse reactions described below and elsewhere in the labeling include:
Pancreatitis
Sphincter of Oddi Spasm
Hypersensitivity Reactions
Constipation
Because clinical trials are conducted under widely varying conditions, adverse reaction rates in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Over 1700 patients with IBS-D have been treated with 75 or 100 mg of VIBERZI twice daily in controlled trials. Exposures from placebo-controlled clinical trials in adult patients with IBS-D included 1391 exposed for 3 months, 1001 exposed for 6 months and 488 exposed for one year.
Demographic characteristics were comparable between the treatment groups
. Data described below represent pooled data compared to placebo across the randomized trials.
Pancreatitis
Cases of pancreatitis, not associated with sphincter of Oddi spasm, were reported in 2/807 (0.2%) of patients receiving 75 mg and 3/1032 (0.3%) of patients receiving 100 mg VIBERZI twice daily in clinical trials. Of these 5 cases, 3 were associated with excessive alcohol intake, one was associated with biliary sludge, and in one case the patient discontinued VIBERZI 2 weeks prior to the onset of symptoms. All pancreatic events resolved with lipase normalization upon discontinuation of VIBERZI, with 80% (4/5) resolving within 1 week of treatment discontinuation. …
Drug interactions
Tables 2 and 3 include drugs which demonstrated a clinically important drug interaction with VIBERZI or which potentially may result in clinically relevant interactions.
OATP1B1 Inhibitors
Clinical Impact: | Increased exposure to eluxadoline when coadministered with cyclosporine
Intervention: | Administer VIBERZI at a dose of 75 mg twice daily
and monitor patients for impaired mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery and for other eluxadoline-related adverse reactions
.
Examples: | cyclosporine, gemfibrozil, antiretrovirals (atazanavir, lopinavir, ritonavir, saquinavir, tipranavir), rifampin, eltrombopag
Drugs that Cause Constipation
Clinical Impact: | Increased risk for constipation related adverse reactions and potential for constipation related serious adverse reactions
Intervention: | Avoid use with other drugs that may cause constipation ; loperamide may be used occasionally for acute management of severe diarrhea but avoid chronic use. Discontinue loperamide immediately if constipation occurs. …
About this medicine
The active ingredient in VIBERZI is eluxadoline, a mu-opioid receptor agonist.
The full chemical name is 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid.
Eluxadoline has a molecular weight of 569.65 and a molecular formula of C32H35N5O5. The chemical structure of eluxadoline is:
VIBERZI is available as 75 mg and 100 mg tablets for oral administration. In addition to the active ingredient, eluxadoline, each tablet contains the following inactive ingredients: silicified microcrystalline cellulose, colloidal silica, crospovidone, mannitol, magnesium stearate, and Opadry II (partially hydrolyzed polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide yellow, and iron oxide red).
How it works: Eluxadoline is a mu-opioid receptor agonist; eluxadoline is also a delta opioid receptor antagonist and a kappa opioid receptor agonist. The binding affinities (Ki) of eluxadoline for the human mu and delta opioid receptors are 1.8 nM and 430 nM, respectively. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7821bd40-4c84-4984-951b-6436ae20421a. Read the full official label on DailyMed.
Related medicines
Omeprazole Pantoprazole Fluoxetine Amoxicillin Famotidine Ondansetron Esomeprazole Docusate